Literature DB >> 1381007

Prevention of catecholamine-induced cardiac damage and death with a nucleoside transport inhibitor.

H Van Belle1, W Verheyen, K Ver Donck, P A Janssen, J I Robertson.   

Abstract

The effect of a potent and specific nucleoside transport inhibitor, R 75,231, on catecholamine-induced cardiac toxicity has been studied in rabbits. Epinephrine (1 mg/kg) or norepinephrine (2.5 mg/kg) subcutaneously were lethal in 25 (42%) of 60 control animals, while survivors showed major myocardial damage, as judged from high plasma lactate dehydrogenase (LDH) and its myocardial isoenzyme (LDH1) after 24 h. When a low dose of R 75,231 (0.1 mg/kg) was given intravenously either 1 h before or 1 h after the catecholamine insult, only 1 of 60 animals died. The plasma total LDH and the LDH1 myocardial isoenzyme were low in these animals compared with untreated survivors. Studies ex vivo on isolated perfused hearts confirmed that with treatment using R 75,231, there was both left ventricular nucleoside retention and functional preservation after in vivo exposure of the animals to epinephrine. R 75,231 did not affect the peripheral venous hyperglycemic response to epinephrine. Nucleoside transport inhibition offers a new approach to the prevention and treatment of several cardiac disorders characterized by a pathogenic effect of catecholamines.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381007     DOI: 10.1097/00005344-199208000-00001

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine.

Authors:  E Snoeck; P Jacqmin; A Van Peer; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1999-06

2.  The antiarrhythmic effects of the nucleoside transporter inhibitor, R75231, in anaesthetized pigs.

Authors:  C L Wainwright; J R Parratt; H Van Belle
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

3.  Studies of the nucleoside transporter inhibitor, draflazine, in the human myocardium.

Authors:  M Böhm; C Weinhold; R H Schwinger; J Müller-Ehmsen; D Böhm; H Reichenspurner; B Reichart; E Erdmann
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

Review 4.  Purine metabolism in the heart. Strategies for protection against myocardial ischaemia.

Authors:  K Ver Donck
Journal:  Pharm World Sci       Date:  1994-04-15

5.  Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection.

Authors:  G A Rongen; P Smits; K Ver Donck; J J Willemsen; R A De Abreu; H Van Belle; T Thien
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

Review 6.  Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM?

Authors:  P Smits; T Thien
Journal:  Diabetologia       Date:  1995-01       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.